AU2002218311A1 - Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease - Google Patents

Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease

Info

Publication number
AU2002218311A1
AU2002218311A1 AU2002218311A AU1831102A AU2002218311A1 AU 2002218311 A1 AU2002218311 A1 AU 2002218311A1 AU 2002218311 A AU2002218311 A AU 2002218311A AU 1831102 A AU1831102 A AU 1831102A AU 2002218311 A1 AU2002218311 A1 AU 2002218311A1
Authority
AU
Australia
Prior art keywords
treatment
inflammatory bowel
bowel disease
protein transferase
transferase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218311A
Other languages
English (en)
Inventor
Charles Ronald Bowden
David William End
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2002218311A1 publication Critical patent/AU2002218311A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002218311A 2000-11-28 2001-11-20 Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease Abandoned AU2002218311A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25334600P 2000-11-28 2000-11-28
US60253346 2000-11-28
PCT/EP2001/013540 WO2002043733A1 (fr) 2000-11-28 2001-11-20 Inhibiteurs de farnesyl proteine transferase destines au traitement d'une maladie intestinale inflammatoire

Publications (1)

Publication Number Publication Date
AU2002218311A1 true AU2002218311A1 (en) 2002-06-11

Family

ID=22959893

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218311A Abandoned AU2002218311A1 (en) 2000-11-28 2001-11-20 Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease

Country Status (11)

Country Link
US (1) US20040044032A1 (fr)
EP (1) EP1339407B1 (fr)
JP (1) JP4231691B2 (fr)
AT (1) ATE323490T1 (fr)
AU (1) AU2002218311A1 (fr)
CY (1) CY1106122T1 (fr)
DE (1) DE60118953T2 (fr)
DK (1) DK1339407T3 (fr)
ES (1) ES2261523T3 (fr)
PT (1) PT1339407E (fr)
WO (1) WO2002043733A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089504A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
EP1732549A4 (fr) * 2004-03-18 2009-11-11 Brigham & Womens Hospital Procedes pour le traitement de synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
ES2403060T3 (es) 2004-11-05 2013-05-13 Janssen Pharmaceutica Nv Uso terapéutico de inhibidores de la farnesiltransferasa y métodos de control de la eficacia de los mismos.
CA2634598A1 (fr) 2005-12-23 2007-07-05 Link Medicine Corporation Traitement de formes de synucleinopathie
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
PT2909192T (pt) 2012-10-16 2017-08-04 Janssen Pharmaceutica Nv Moduladores de ror-gama-t quinolinilo ligados por metileno
MX2015004784A (es) 2012-10-16 2015-08-14 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a fenilo de receptor nuclear de acido retinoico-gamma-t.
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
CN105848483A (zh) 2013-10-15 2016-08-10 詹森药业有限公司 RORγt 的喹啉基调节剂
WO2015057629A1 (fr) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Modulateurs quinolinyl à liaison alkyle de roryt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
HUE044698T2 (hu) 2015-08-17 2019-11-28 Kura Oncology Inc Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
CN110325212B (zh) 2016-11-03 2022-03-22 库拉肿瘤学公司 用于治疗癌症的方法的法尼基转移酶抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007498A1 (fr) * 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale
US5470832A (en) * 1994-01-31 1995-11-28 Merck & Co., Inc. Inhibitors of geranylgeranyl-protein transferase
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
TW316902B (fr) * 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
IL123568A (en) * 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5929077A (en) * 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
GB2323783A (en) * 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
IL130363A (en) * 1997-04-25 2002-08-14 Janssen Pharmaceutica Nv Quinazolines that inhibit frenzyl transferase, their preparation and pharmaceutical preparations containing them
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
WO1999026657A1 (fr) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibiteurs de la monoxyde d'azote-synthase
KR100712226B1 (ko) * 1998-12-23 2007-04-27 얀센 파마슈티카 엔.브이. 1,2-어닐링된 퀴놀린 유도체

Also Published As

Publication number Publication date
ES2261523T3 (es) 2006-11-16
EP1339407B1 (fr) 2006-04-19
EP1339407A1 (fr) 2003-09-03
ATE323490T1 (de) 2006-05-15
US20040044032A1 (en) 2004-03-04
DK1339407T3 (da) 2006-08-14
WO2002043733A1 (fr) 2002-06-06
JP2004514695A (ja) 2004-05-20
PT1339407E (pt) 2006-08-31
JP4231691B2 (ja) 2009-03-04
CY1106122T1 (el) 2011-06-08
DE60118953T2 (de) 2007-01-11
DE60118953D1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
AU2002218311A1 (en) Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
AU2001233726A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
MY127290A (en) New use of flibanserin
WO2003042246A3 (fr) Traitement medical
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
GB0112348D0 (en) Compounds
IN2005KO00312A (fr)
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
BR0211972A (pt) Composição oftálmica
AU2002363182A1 (en) Smad7 inhibitors for the treatment of cns diseases
GB0002336D0 (en) Medicaments
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
MXPA04005809A (es) Inhibidores de proteinas quinasas.
GB9907571D0 (en) Compounds
SE0004827D0 (sv) Therapeutic compounds
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
AU3071999A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
TW200509945A (en) Agent for treatment of anal disease
PL359727A1 (en) Crystalline pharmaceutical
AU2002210286A1 (en) Medicine intended for treatment of multiple sclerosis